Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 153

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 153
---
’s shares of common stock commenced trading on OTCQB as of December 2, 2025. 85 MARKET PRICE AND DIVIDEND INFORMATION Market Price On October 29, 2025, we received the determination of the October 2025 Panel to deny our request to continue the listing of our Common Stock on Nasdaq and that the trading in our securities would be suspended at the open of trading on October 31, 2025. We submitted a request for review of the Panel’s decision by the Nasdaq Listing and Hearing Review Council. The Company’s shares of common stock commenced trading on OTCQB as of December 2, 2025. The last bid price of our Common Stock as reported on OTCQB on December 4, 2025 was $0.113 per share and of our Public Warrants as reported on OTCID on December 4, 2025 was $0.0091 per warrant. Holders As of November 24, 2025, there were 115 holders of record of our Common Stock and 32 holders of record of our Public Warrants. The numbers of holders of record do not include for example a substantially greater number of “street name” holders or beneficial holders whose securities are held of record by banks, brokers and other financial institutions. Dividend Policy We have not paid any cash dividends to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements, and general financial condition. The payment of any cash dividends will be within the discretion of our Board at such time. 86 BUSINESS Overview We are an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Our proprietary approach to T cell engineering, which enables us to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Our novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in pathways that employ both cytotoxic and phagocytic mechanisms to destroy cancer cells, creating what we refer to as Chimeric Engulfment Receptor T (“CER-T”) cells. Our lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. Unlike currently approved chimeric antigen receptor (“CAR-T”) therapies which have largely been active in hematological B cell malign